Vas Lakshmi, Pai Renuka
Ashirvad Institute for Pain Management and Research, Mumbai, Maharashtra, India.
Indian J Palliat Care. 2019 Jan-Mar;25(1):93-102. doi: 10.4103/IJPC.IJPC_24_18.
Existing interventions for postmastectomy pain syndrome (PMPS) address the neural component while overlooking a possible myofascial component.
The aim of the study is to investigate the myofascial contribution to PMPS, by examining the effectiveness of myofascial trigger point release by ultrasound-guided dry needling (USGDN).
This retrospective review assessed the efficacy of USGDN in addressing myofascial pain in twenty consecutive patients with treatment-refractory PMPS. Patients in Group 1 ( = 16) received USGDN after neural interventions (NIs) such as neuraxial blocks, intrathecal pump implant, or pulsed radiofrequency, while those in Group 2 ( = 4) received USGDN alone. Outcome measures were changes in Numerical Rating Scale (NRS), PainDETECT (PD), Disabilities of Arm, Shoulder, and Hand (DASH), Patient Health Questionnaire-9 (PHQ-9) scores, and opioid use.
In Group 1, the mean (standard deviation) NRS and PD scores (9.6 [0.9] and 28.3 [4.3], respectively, at baseline) reduced to 5.2 (1.1) and 16.1 (3.7) at 1-week post-NI. The post-NI DASH reduction was below the cutoff for clinical relevance (80.9 [10.5] at baseline vs. 71.1 [10.5] post-NI). The opioid dose remained unchanged. Following USGDN, NRS, PD, and DASH scores further reduced to 2.3 (0.8), 6.6 (1.2), and 34.6 (14.4), respectively. Patients receiving USGDN alone also showed reduction in NRS, PD, and DASH (7.8 [1.7], 20.0 [8.0], and 61.0 [14.4] at baseline vs. 1.3 [0.5], 6.0 [1.6], and 22.5 [10.4] post-USGDN, respectively). In all patients, opioid use and PHQ-9 scores reduced only post-USGDN.
USGDN reduced pain, disability, and opioid use, whereas NI reduced only pain. This suggests a myofascial contribution to pain and disability in PMPS.
现有的乳房切除术后疼痛综合征(PMPS)干预措施针对神经成分,而忽略了可能存在的肌筋膜成分。
本研究旨在通过检查超声引导下干针穿刺(USGDN)松解肌筋膜触发点的有效性,来探究肌筋膜对PMPS的影响。
这项回顾性研究评估了USGDN对20例治疗难治性PMPS患者肌筋膜疼痛的疗效。第1组(n = 16)患者在接受诸如神经轴阻滞、鞘内泵植入或脉冲射频等神经干预(NIs)后接受USGDN,而第2组(n = 4)患者仅接受USGDN。观察指标包括数字评定量表(NRS)、疼痛检测量表(PD)、手臂、肩部和手部功能障碍量表(DASH)、患者健康问卷-9(PHQ-9)评分的变化以及阿片类药物的使用情况。
在第1组中,平均(标准差)NRS和PD评分(基线时分别为9.6 [0.9]和28.3 [4.3])在NI后1周降至5.2(1.1)和16.1(3.7)。NI后DASH评分的降低未达到临床相关性的临界值(基线时为80.9 [10.5],NI后为71.1 [10.5])。阿片类药物剂量保持不变。在接受USGDN后,NRS、PD和DASH评分进一步分别降至2.3(0.8)、6.6(1.2)和34.6(14.4)。仅接受USGDN的患者NRS、PD和DASH评分也有所降低(基线时分别为7.8 [1.7]、20.0 [8.0]和61.0 [14.4],USGDN后分别为1.3 [0.5]、6.0 [1.6]和22.5 [10.4])。在所有患者中,仅在接受USGDN后阿片类药物使用和PHQ-9评分降低。
USGDN减轻了疼痛、功能障碍并减少了阿片类药物的使用,而NI仅减轻了疼痛。这表明肌筋膜对PMPS的疼痛和功能障碍有影响。